Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Rhea-AI Summary

Rigel Pharmaceuticals (Nasdaq: RIGL) has scheduled its fourth quarter and full year 2024 financial results announcement for Tuesday, March 4, 2025, after market close. The announcement will be followed by a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time), where senior management will discuss financial results and provide a business update.

Participants can join the conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The call and accompanying slides will also be webcast live from the Investor Relations section of Rigel's website and archived for 90 days afterward.

Rigel Pharmaceuticals is a biotechnology company founded in 1996 that focuses on discovering, developing, and providing novel therapies for patients with hematologic disorders and cancer. The company is headquartered in South San Francisco, California.

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2024 financial results after market close on Tuesday, March 4, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.

Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Contact for Investors & Media:  
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com 

Media:
David Rosen
Argot Partners
Phone: 646.461.6387
Email: david.rosen@argotpartners.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-full-year-2024-financial-results-and-business-update-302384250.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

When will Rigel Pharmaceuticals (RIGL) report its Q4 and full year 2024 financial results?

Rigel Pharmaceuticals will report its fourth quarter and full year 2024 financial results after market close on Tuesday, March 4, 2025.

How can investors access RIGL's Q4 2024 earnings call?

Investors can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international), or via webcast from Rigel's website at www.rigel.com.

What time is Rigel's (RIGL) Q4 2024 earnings conference call scheduled?

Rigel's conference call is scheduled for 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on Tuesday, March 4, 2025.

What therapeutic areas does Rigel Pharmaceuticals (RIGL) focus on?

Rigel Pharmaceuticals focuses on discovering, developing, and providing novel therapies for patients with hematologic disorders and cancer.

How long will RIGL's Q4 2024 earnings webcast be available for replay?

The webcast will be archived and available for replay for 90 days after the call via Rigel's website.